Business Wire

ZAYO-GROUP

16.1.2023 14:01:42 CET | Business Wire | Press release

Share
Zayo Boosts Infrastructure Leadership in Europe with Pivotal Fiber Expansion Connecting Global Internet Hubs of Paris and Marseille

Zayo Group Holdings, Inc., a leading global communications infrastructure platform, announced the deployment of a new 400G enabled route connecting Paris and Marseille—including first-in-market network hardening of this critical route leveraging next-generation fiber technologies—to provide enterprises with an easier and more secure way to transport rapidly increasing high-bandwidth traffic from these top-ten global internet hubs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005067/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Map of Zayo's new 400G enabled route connecting Paris and Marseille (Graphic: Business Wire)

“We are continuously expanding, improving and diversifying our network in order to support our customers with their increasing bandwidth,” said Yannick Leboyer, Europe Chief Operating Officer at Zayo. “With several new subsea cable projects set to deploy in the coming years, Marseille is on its way to becoming one of the top five internet connectivity hubs globally, and Zayo is uniquely positioned to provide the necessary infrastructure to support this growth. The Paris-to-Marseille route is built to support and transport the fast-paced bandwidth growth and increasingly high demand for connectivity in these markets, giving customers a more reliable, scalable and secure way to share data to the rest of Europe and the U.S.”

Paris is the fourth largest internet connectivity hub in the world, and Marseille, a crossroad of several major exchanges between terrestrial and submarine networks, is projected to move from the seventh to the fifth largest global internet hub in the next three years. With six new subsea cables in Marseille scheduled for completion, including key gateways to Asia, Africa and the Middle East, capacity demands in Marseille are expected to quadruple by 2026. This is creating a rapidly increasing need for enterprises to transport traffic growth from these hubs throughout Europe and to other key commerce centers across the globe.

The new Paris-to-Marseille route from Zayo provides 24 terabytes of total expected capacity per fiber pair, critical triversity options, and 400G enablement for enterprises to manage this capacity growth and ensure secure, resilient connectivity to the rest of Europe and the United States. Beyond capacity, Zayo is hardening its network with new fiber technologies, making Zayo the first carrier with this next-generation fiber on the route connecting Paris to Marseille.

The route will also provide direct access to Bordeaux—the landing city for Amitié, a new private transatlantic cable that will connect the U.S. with the UK and France. Once ready for service, the connection will enable direct access to Asia, Africa, and the Middle East.

This latest investment from Zayo is part of the company’s overall strategy to overlay its European backbone and deliver high-capacity bandwidth across Europe, following the completion of its Zeus subsea cable in 2022, which provides the strongest connection between the UK and continental Europe. To date, Zayo owns and operates 2.2 million kilometers of fiber and connects 16 key metro markets and nine countries across Europe.

To learn more about Zayo’s global network, please visit https://www.zayo.com/network/.

About Zayo Group Holdings, Inc.

Zayo Group Holdings, Inc. is the leading global communications infrastructure platform, delivering a range of solutions, including fiber & transport, packet and managed edge services. Zayo owns and operates a Tier 1 IP backbone spanning 137,000 miles across North America and Europe. By providing this mission-critical bandwidth to its category-leading customers across the wireless, hyperscale, media, tech and finance industries, Zayo is fueling the innovations that are transforming society. For more information, visit https://zayo.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005067/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye